Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Amplia Therapeutics Ltd

ATX.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: BUY

Last Close

$0.06

▼ -5.62%

Market Cap $30.30M · Vol 1.15M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$30.30M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

25.93

Momentum

Beta

-0.07

vs Market

52W High

$0.19

69.01% below

52W Low

$0.05

10.92% above

Volume

1.15M

Avg 1.05M

P/B

3.05

Price-to-book

ROE

N/A

Return on equity

Free Float

90.44%

Public shares

Shariah Compliance8 STANDARDS

✗ Amplia Therapeutics Ltd (ATX.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ATX.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.00%

-26.96%

-32.80%

-44.00%

YTD

-44.00%

-37.78%

+15.06%

-55.44%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-5,317,916.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-23.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.05
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	513.31M

Technical Indicators

50-Day SMA	$0.08
200-Day SMA	$0.09
RSI (14)	25.93
Beta	-0.07
52-Week High	$0.19
52-Week Low	$0.05

Volume Today	1.15M
Avg Daily Volume (30D)	1.05M
Relative Volume	1.10x
Volatility (10D)	57.96
Volatility (30D)	82.17
Free Float	90.44%

Analyst Consensus

BUY

Current Price $0.06

Mean Target $0.30

52W Low$0.05 52W High$0.19

Current

Target

$0.05 $0.19

Current Analyst target

+405.98% upside potential · 0 analysts

Identifiers

ExchangeASX

FIGIBBG005M56XJ3

ISINAU0000023822

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 27, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.